Loading...

Prometic Life Sciences

TSX:PLI
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PLI
TSX
CA$225M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. The last earnings update was 129 days ago. More info.


Add to Portfolio Compare Print
  • Prometic Life Sciences has significant price volatility in the past 3 months.
PLI Share Price and Events
7 Day Returns
1.7%
TSX:PLI
-0.1%
CA Biotechs
-0%
CA Market
1 Year Returns
-77.6%
TSX:PLI
-20.1%
CA Biotechs
2.6%
CA Market
PLI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Prometic Life Sciences (PLI) 1.7% 0% -10.3% -77.6% -90.2% -73.2%
CA Biotechs -0.1% -0.1% 13.5% -20.1% -41.4% -44%
CA Market -0% 0.4% 15% 2.6% 16.8% 5.3%
1 Year Return vs Industry and Market
  • PLI underperformed the Biotechs industry which returned -20.1% over the past year.
  • PLI underperformed the Market in Canada which returned 2.6% over the past year.
Price Volatility
PLI
Industry
5yr Volatility vs Market

PLI Value

 Is Prometic Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Prometic Life Sciences to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Prometic Life Sciences.

TSX:PLI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.9%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for TSX:PLI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.79
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.789 (1 + (1- 26.5%) (67.73%))
2.125
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (2 * 5.96%)
13.87%

Discounted Cash Flow Calculation for TSX:PLI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Prometic Life Sciences is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

TSX:PLI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 13.87%)
2019 -59.76 Analyst x1 -52.48
2020 45.26 Analyst x1 34.91
2021 101.97 Analyst x1 69.07
2022 174.90 Analyst x1 104.04
2023 246.84 Analyst x1 128.95
2024 307.27 Est @ 24.48% 140.97
2025 361.73 Est @ 17.72% 145.75
2026 408.71 Est @ 12.99% 144.62
2027 448.26 Est @ 9.68% 139.30
2028 481.25 Est @ 7.36% 131.34
Present value of next 10 years cash flows CA$986.46
TSX:PLI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= CA$481.25 × (1 + 1.95%) ÷ (13.87% – 1.95%)
CA$4,115.91
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$4,115.91 ÷ (1 + 13.87%)10
CA$1,123.28
TSX:PLI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$986.46 + CA$1,123.28
CA$2,109.74
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$2,109.74 / 739.13
CA$2.85
TSX:PLI Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$2.85
Current discount Discount to share price of CA$0.31
= -1 x (CA$0.31 - CA$2.85) / CA$2.85
89.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Prometic Life Sciences is available for.
Intrinsic value
>50%
Share price is CA$0.31 vs Future cash flow value of CA$2.85
Current Discount Checks
For Prometic Life Sciences to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Prometic Life Sciences's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Prometic Life Sciences's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Prometic Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Prometic Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSX:PLI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in CAD CA$-0.18
TSX:PLI Share Price ** TSX (2019-03-22) in CAD CA$0.31
North America Biotechs Industry PE Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 18.88x
Canada Market PE Ratio Median Figure of 551 Publicly-Listed Companies 14.94x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Prometic Life Sciences.

TSX:PLI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSX:PLI Share Price ÷ EPS (both in CAD)

= 0.31 ÷ -0.18

-1.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prometic Life Sciences is loss making, we can't compare its value to the North America Biotechs industry average.
  • Prometic Life Sciences is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Prometic Life Sciences's expected growth come at a high price?
Raw Data
TSX:PLI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
74.3%per year
North America Biotechs Industry PEG Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 1.36x
Canada Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Prometic Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Prometic Life Sciences's assets?
Raw Data
TSX:PLI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in CAD CA$0.05
TSX:PLI Share Price * TSX (2019-03-22) in CAD CA$0.31
Canada Biotechs Industry PB Ratio Median Figure of 39 Publicly-Listed Biotechs Companies 5.65x
Canada Market PB Ratio Median Figure of 2,351 Publicly-Listed Companies 1.57x
TSX:PLI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSX:PLI Share Price ÷ Book Value per Share (both in CAD)

= 0.31 ÷ 0.05

6.75x

* Primary Listing of Prometic Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Prometic Life Sciences is overvalued based on assets compared to the CA Biotechs industry average.
X
Value checks
We assess Prometic Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Prometic Life Sciences has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PLI Future Performance

 How is Prometic Life Sciences expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
74.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Prometic Life Sciences expected to grow at an attractive rate?
  • Prometic Life Sciences's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
  • Prometic Life Sciences's earnings growth is expected to exceed the Canada market average.
  • Prometic Life Sciences's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
TSX:PLI Future Growth Rates Data Sources
Data Point Source Value (per year)
TSX:PLI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 74.3%
TSX:PLI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 45.7%
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 30.1%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 22.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 18.1%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSX:PLI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSX:PLI Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 788 1
2022-12-31 542 1
2021-12-31 313 1
2020-12-31 255 15 11 2
2019-12-31 79 -64 -69 5
2018-12-31 43 -76 -114 4
TSX:PLI Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-09-30 43 -85 -131
2018-06-30 55 -105 -118
2018-03-31 39 -120 -115
2017-12-31 39 -123 -110
2017-09-30 37 -129 -109
2017-06-30 16 -118 -119
2017-03-31 16 -114 -112
2016-12-31 16 -98 -101
2016-09-30 26 -76 -74
2016-06-30 28 -66 -58
2016-03-31 28 -59 -48
2015-12-31 25 -46 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Prometic Life Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Prometic Life Sciences's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSX:PLI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Prometic Life Sciences Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:PLI Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.02 0.02 0.02 1.00
2019-12-31 -0.09 -0.09 -0.09 2.00
2018-12-31 -0.14 -0.10 -0.18 3.00
TSX:PLI Past Financials Data
Date (Data in CAD Millions) EPS *
2018-09-30 -0.18
2018-06-30 -0.17
2018-03-31 -0.16
2017-12-31 -0.16
2017-09-30 -0.16
2017-06-30 -0.19
2017-03-31 -0.18
2016-12-31 -0.17
2016-09-30 -0.13
2016-06-30 -0.10
2016-03-31 -0.08
2015-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Prometic Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Prometic Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Prometic Life Sciences has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PLI Past Performance

  How has Prometic Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Prometic Life Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Prometic Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Prometic Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Prometic Life Sciences's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Prometic Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Prometic Life Sciences Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSX:PLI Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 43.37 -130.69 50.14
2018-06-30 55.08 -117.76 51.57
2018-03-31 38.54 -115.01 52.69
2017-12-31 39.12 -109.73 51.93
2017-09-30 36.63 -108.76 32.47
2017-06-30 16.33 -118.79 31.29
2017-03-31 16.01 -111.63 28.42
2016-12-31 16.39 -100.81 26.30
2016-09-30 26.35 -74.17 21.82
2016-06-30 28.27 -57.83 19.47
2016-03-31 27.87 -47.76 18.05
2015-12-31 24.53 -50.96 16.58
2015-09-30 21.01 -31.07 15.09
2015-06-30 17.67 -41.12 14.15
2015-03-31 19.18 -4.88 13.37
2014-12-31 23.01 5.94 12.15
2014-09-30 17.54 -10.29 12.06
2014-06-30 21.19 3.73 10.85
2014-03-31 21.94 -22.68 8.96
2013-12-31 20.64 -16.49 8.33
2013-09-30 23.89 -8.30 6.49
2013-06-30 25.60 -0.58 5.76
2013-03-31 26.71 2.67 5.93
2012-12-31 23.32 0.23 5.83
2012-09-30 23.42 2.60 5.31
2012-06-30 19.09 -1.81 5.48
2012-03-31 15.83 -4.27 5.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Prometic Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Prometic Life Sciences has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Prometic Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Prometic Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Prometic Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PLI Health

 How is Prometic Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Prometic Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Prometic Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Prometic Life Sciences's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Prometic Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Prometic Life Sciences Company Filings, last reported 5 months ago.

TSX:PLI Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 63.99 152.68 21.35
2018-06-30 89.88 126.20 11.82
2018-03-31 120.86 110.02 13.87
2017-12-31 143.43 87.99 23.17
2017-09-30 172.61 66.14 29.06
2017-06-30 129.60 67.54 14.29
2017-03-31 152.73 48.40 20.12
2016-12-31 159.34 48.12 38.87
2016-09-30 148.94 41.61 39.00
2016-06-30 176.39 40.32 64.33
2016-03-31 137.89 42.23 34.45
2015-12-31 145.33 22.00 29.29
2015-09-30 156.38 21.45 42.48
2015-06-30 166.61 20.91 56.66
2015-03-31 93.06 22.46 20.49
2014-12-31 104.43 23.24 27.10
2014-09-30 42.40 22.29 10.38
2014-06-30 56.34 10.10 2.04
2014-03-31 10.90 9.71 10.31
2013-12-31 18.64 9.26 17.40
2013-09-30 0.61 9.37 8.03
2013-06-30 4.58 4.38 5.74
2013-03-31 6.26 4.53 7.55
2012-12-31 5.82 6.47 1.21
2012-09-30 -4.60 6.43 0.56
2012-06-30 -7.55 6.35 0.67
2012-03-31 -10.12 5.91 0.04
  • Prometic Life Sciences's level of debt (238.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1163.6% vs 238.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Prometic Life Sciences has less than a year of cash runway based on current free cash flow.
  • Prometic Life Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 22.9% each year.
X
Financial health checks
We assess Prometic Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Prometic Life Sciences has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PLI Dividends

 What is Prometic Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Prometic Life Sciences dividends. Estimated to be 0% next year.
If you bought CA$2,000 of Prometic Life Sciences shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Prometic Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Prometic Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSX:PLI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSX:PLI Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Prometic Life Sciences has not reported any payouts.
  • Unable to verify if Prometic Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Prometic Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Prometic Life Sciences has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Prometic Life Sciences's dividends in 3 years as they are not expected to pay a notable one for Canada.
X
Income/ dividend checks
We assess Prometic Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Prometic Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Prometic Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PLI Management

 What is the CEO of Prometic Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Simon Best
COMPENSATION CA$277,333
AGE 61
TENURE AS CEO 0.3 years
CEO Bio

Prof. Simon Geoffrey Best, OBE, FRSE has been President and Chief Executive Officer of Prometic Life Sciences Inc. since December 2018. He serves as the Chief Executive Officer of Geron Bio-Med. Prof. Best serves as an Entrepreneur-in-Residence and a Partner of TVM Capital (Munich, Germany). He co-founded PAR Equity LLP in 2008 and serves as its Non-Executive Partner. Prof. Best has over 25 years experience across the life science sector in pharmaceuticals, agbiotech, chemicals and industrial enzymes. Prof. Best held also the position of Chief Executive Officer at Aquapharm Biodiscovery Ltd. (a company in the sector of drug discovery) from May 2010 to November 2012. Through this time, Prof. Best has gained significant entrepreneurial and senior management experience of raising finance, deal formation and product commercialization. Prof. Best co-founded Ardana Plc in 2000 and served as its Chief Executive Officer until 2004. He served as the Managing Director and Chief Executive Officer of Zeneca Plant Sciences, where he managed its joint ventures and acquisition programmes. Prof. Best served as Founding Chief Executive Officer of Roslin Bio-Med and was responsible for the commercialization of the technology that developed Dolly the Sheep, including the merger of the business into the US-listed biotech company Geron Corp. He served as the Interim Chief Executive Officer of ProMetic Life Sciences Inc. since December 19, 2018 until December 2018 and serves as its Chairman. He serves as Director of ProMetic Life Sciences Inc., since December 19, 2018. He served as an Independent Director of ProMetic Life Sciences Inc., since May 14, 2014 until December 19, 2018. He serves as Chairman of Advisory Panel at PathXL Ltd. He serves as Chairman of Advisory Board at PAR Equity LLP. Prof. Best served as Chairman of Ardana Bioscience Ltd. He serves as Chairman of Edinburgh University Technology Fund. Prof. Best is a seasoned veteran of the global Life science Industry with experience, both as a Founder, Chief Executive Officer and Chairman or board member of entrepreneurial companies and as the Chairman or board member of major industry bodies and public sector institutions in the UK, USA, Europe, Asia and Latin America. He is also an experienced Angel, Venture Capital and Private Equity investor. Prof. Best served as the Chairman of BioIndustry Association (BIA) from 2006 to 2007 and its Vice Chairman from 1994 to 1996. He served as Non-Executive Chairman of Ardana Plc since March 3, 2005. From 2005 to 2010, he built a portfolio of Chair, Board and Advisory roles with Biotech Companies. He served as Chairman of the Board at ICRISAT (Hyderabad, India). Prof. Best served as an Executive Chairman of Ardana Plc from May 2004 to March 2005. He served as a Non-Executive Chairman of Neuro3d S.A., since September 2005. He served as a Vice-Chairman of BIO, USA from 1994 to 1996. He served as a Governor of the Food and Agriculture Section of the World Economic Forum (WEF) from 1994 to 1998. Prof. Best serves as a Director of Ohmedics and Matrix Genetics, LLC. He serves as a Member of Advisory Panel at Par Equity LLP. He has been a Director of DIREVO Biotech AG since July 2007. He serves as a Director of PathXL Ltd. Prof. Best serves as a Non-Executive Director of Avesthagen Pvt. Ltd. He served as a Director of Avesthagen Limited. He served as a Non-Executive Director of Ardana Plc since May 2004. He serves as a Non Executive Director of Polytherics. Prof. Best served as a Director of Biotechnology Industry Organization. He served as an Executive Director of Aquapharm Biodiscovery Limited. Prof. Best served as a Director of Targeted Growth, Inc. from 2008 to 2010. He served as a Director of Entelos Inc., since December 2005. From November 2015 to December 2017, Prof. Best served on the board of Evofem Inc., a women's health company based in San Diego. Prof. Best served as a Director of Avestha Gengraine Technologies Pvt Ltd. Prof. Best serves as a Director of Advisory Board at PAR Equity LLP. He served as a Director of Neuro3d S.A. He served as an Executive Board Member and as Vice-Chairman of the UK India Business Council (UKIBC) since March 2008. He served as a Member of Supervisory Board at DIREVO Biotech AG. He served as a Member of Advisory Board at the Fraunhofer Center for System Biology in Santiago, Chile since December 2012. From March 2010 to August 2015, Prof. Best was the Chairman of Edinburgh BioQuarter with responsibility for company formation and technology transfer for the University of Edinburgh. He serves as a Non-Executive Director of International Potato Centre and is a Member of the UK Bioscience Leadership Council (BLC). He has been a Visiting Professor of Medicine by the University of Edinburgh since August 2008. In 1999, Prof. Best was nominated by the World Economic Forum as a “Global Leader of Tomorrow“ and in 2000 as a “Technology Pioneer of the Year.“ In September 1999, he was nominated as “Science and Technology Venturer of the Year“ by the Financial Times. In 2007, Prof. Best was elected a Fellow of the Royal Society of Edinburgh (FRSE). He was awarded the London Business School Alumni Achievement Prize in 2007. In 2008, he was awarded an OBE by Queen Elizabeth II. Prof. Best holds a Bachelor of Music from the University of York in 1977 and an MBA from London Business School (LBS) in 1985 where he was the recipient of the Alan Patricof and Associates (APAX) Venture Capital prize. He was awarded an Honorary Ph.D. from the University of York for his contributions to Music, Biotechnology and Medicine in 2004.

CEO Compensation
  • Simon's compensation has increased whilst company is loss making.
  • Simon's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Prometic Life Sciences management team in years:

2.7
Average Tenure
68
Average Age
  • The tenure for the Prometic Life Sciences management team is about average.
Management Team

Simon Best

TITLE
Chairman
COMPENSATION
CA$277K
AGE
61
TENURE
0.3 yrs

Bruce Pritchard

TITLE
COO & Interim CFO
COMPENSATION
CA$3M
TENURE
1.6 yrs

Patrick Sartore

TITLE
Chief Legal Officer & Corporate Secretary
COMPENSATION
CA$2M
TENURE
3.8 yrs

Bruce Wendel

TITLE
Chief Business Development Officer
COMPENSATION
CA$121K
AGE
64
TENURE
0.9 yrs

John Moran

TITLE
Chief Medical Officer
COMPENSATION
CA$2M
AGE
72
TENURE
5 yrs

Frédéric Dumais

TITLE
Senior Director of Communications & Investor Relations

John Bienenstock

TITLE
Member of Advisory Committee - Therapeutics
COMPENSATION
CA$10K
AGE
81

Christopher Penney

TITLE
Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc
COMPENSATION
CA$285K
TENURE
18.2 yrs

Bob Rohwer

TITLE
Member of Scientific Advisory Committee - PRDT

Volker Helrich

TITLE
Member of Scientific Advisory Committee - Therapeutics
Board of Directors Tenure

Average tenure and age of the Prometic Life Sciences board of directors in years:

3.6
Average Tenure
57.5
Average Age
  • The tenure for the Prometic Life Sciences board of directors is about average.
Board of Directors

Paul Mesburis

TITLE
Independent Director
COMPENSATION
CA$162K
AGE
48
TENURE
10.2 yrs

Simon Best

TITLE
Chairman
COMPENSATION
CA$277K
AGE
61

Louise Ménard

TITLE
Independent Director
COMPENSATION
CA$159K
AGE
69
TENURE
9.8 yrs

Chuck Kenworthy

TITLE
Non-Independent Director
COMPENSATION
CA$123K
AGE
60
TENURE
5.3 yrs

Kurt Stefan Clulow

TITLE
Non-Independent Director
COMPENSATION
CA$121K
AGE
47
TENURE
4.6 yrs

Ken Galbraith

TITLE
Independent Director
COMPENSATION
CA$138K
AGE
55
TENURE
2.6 yrs

David Jeans

TITLE
Independent Director
COMPENSATION
CA$114K
AGE
68
TENURE
1.8 yrs

Kory Sorenson

TITLE
Non-Executive Director
AGE
50
TENURE
0.8 yrs

Zachary Newton

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Prometic Life Sciences insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
04. Jan 19 Buy Louise Ménard Individual 02. Jan 19 02. Jan 19 21,400 CA$0.29 CA$6,099
01. Jan 19 Buy Paul Mesburis Individual 31. Dec 18 31. Dec 18 22,200 CA$0.27 CA$5,994
01. Jan 19 Buy Simon Best Individual 31. Dec 18 31. Dec 18 50,000 CA$0.30 CA$15,000
23. May 18 Buy Martin Leclerc Individual 22. May 18 22. May 18 15,000 CA$0.78 CA$11,700
03. Apr 18 Buy Martin Leclerc Individual 03. Apr 18 03. Apr 18 20,000 CA$0.74 CA$14,800
X
Management checks
We assess Prometic Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Prometic Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PLI News

Simply Wall St News

Introducing Prometic Life Sciences, The Stock That Tanked 89%

During three years of share price growth, Prometic Life Sciences moved from a loss to profitability. … So given the share price is down it's worth checking some other metrics too. … It's probably worht worth investigating Prometic Life Sciences further; while we may be missing something on this analysis, there might also be an opportunity

Simply Wall St -

When Will ProMetic Life Sciences Inc (TSE:PLI) Breakeven?

ProMetic Life Sciences Inc's (TSE:PLI):. … ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. … The company’s loss has recently broadened since it announced a -CA$110m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$118m, moving it further away from breakeven?

Simply Wall St -

Is ProMetic Life Sciences Inc's (TSE:PLI) CEO Pay Justified?

Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … This is because, if incentives are aligned, more value is created for shareholders which directly impacts your returns as an investor. … CEOs leading companies of similar size and profitability

Simply Wall St -

What You Must Know About ProMetic Life Sciences Inc's (TSE:PLI) Major Investors

In this article, I'm going to take a look at ProMetic Life Sciences Inc’s (TSE:PLI) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … Therefore, it is beneficial for us to examine PLI's ownership structure in more detail. … See our latest analysis for ProMetic Life Sciences

Simply Wall St -

Breakeven On The Horizon For ProMetic Life Sciences Inc (TSE:PLI)

ProMetic Life Sciences Inc's (TSE:PLI):. … ProMetic Life Sciences Inc., a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. … The company’s loss has recently broadened since it announced a -CA$109.73m loss in the full financial year, compared to the latest trailing-twelve-month loss of -CA$115.00m, moving it further away from breakeven.

Simply Wall St -

ProMetic Life Sciences Inc's (TSE:PLI) Earnings Dropped -46.63%, Did Its Industry Show Weakness Too?

Assessing ProMetic Life Sciences Inc's (TSX:PLI) past track record of performance is a valuable exercise for investors. … For ProMetic Life Sciences, its most recent earnings (trailing twelve month) is -CA$108.76M, which, against the previous year's figure, has become more negative. … The most valuable step is to examine company-specific issues ProMetic Life Sciences may be facing and whether management guidance has regularly been met in the past.

Simply Wall St -

Does ProMetic Life Sciences Inc's (TSX:PLI) -30.9% EPS Decline Reflect A Long-Term Trend?

View our latest analysis for ProMetic Life Sciences Was PLI's recent earnings decline indicative of a tough track record? … For ProMetic Life Sciences, the latest earnings -CA$109M, which compared to the prior year's level, has become more negative. … I suggest you continue to research ProMetic Life Sciences to get a better picture of the stock by looking at: 1.

Simply Wall St -

Top TSX High Growth Stock

Stocks such as ProMetic Life Sciences and MedReleaf are considered to be high growth in terms of how much they’re expected to earn and return to shareholders, according to the market. … PLI’s projected future profit growth is a robust 12.38%, with an underlying triple-digit growth from its revenues expected over the upcoming years. … TSX:CBL Future Profit Nov 16th 17 For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.

Simply Wall St -

What Do ProMetic Life Sciences Inc (TSX:PLI) Insiders Know That You Don't?

PLI is one of Canada’s large-cap stocks that saw some insider buying over the past three months, with insiders investing in 226,224 shares during this period. … TSX:PLI Future Profit Nov 3rd 17 Analysts’ expectations for earnings over the next 3 years of 92.97% provides an exceptional outlook for the business which is consistent with the signal company insiders are sending with their net buying activity. … Next Steps: PLI’s net buying tells us the stock is in favour with some insiders, which is relatively consistent with expected earnings growth, as well as the relatively large share price volatility over the same period of trade.

Simply Wall St -

PLI Company Info

Description

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Details
Name: Prometic Life Sciences Inc.
PLI
Exchange: TSX
Founded: 1992
CA$225,434,816
739,130,546
Website: http://www.prometic.com
Address: Prometic Life Sciences Inc.
440, Boulevard Armand-Frappier,
Suite 300,
Laval,
Quebec, H7V 4B4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSX PLI Common Shares The Toronto Stock Exchange CA CAD 28. Jul 1998
OTCPK PFSC.F Common Shares Pink Sheets LLC US USD 28. Jul 1998
DB PJ2 Common Shares Deutsche Boerse AG DE EUR 28. Jul 1998
Number of employees
Current staff
Staff numbers
480
Prometic Life Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/23 23:42
End of day share price update: 2019/03/22 00:00
Last estimates confirmation: 2019/03/11
Last earnings filing: 2018/11/14
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.